2020 ESMO Updates in Lung Cancer: Does 1L Nivolumab–Ipilimumab Boost Unresectable Mesothelioma OS? Did the PACIFIC Trial Demonstrate Durable Benefit With Durvalumab After cCRT in Stage 3 NSCLC?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

2020 ESMO Updates in Lung Cancer: Does 1L Nivolumab–Ipilimumab Boost Unresectable Mesothelioma OS? Did the PACIFIC Trial Demonstrate Durable Benefit With Durvalumab After cCRT in Stage 3 NSCLC?

By 2020 Virtual ESMO Review FEATURING Martin Dietrich

616 views

November 4, 2020

Comments 0

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

2.5K views

7 months ago

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

1.3K views

8 months ago

Year in Review: Lung Cancer

Balazs Halmos

2.6K views

10 months ago

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

810 views

5 months ago

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

6.4K views

2 years ago

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views

7 months ago

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

493 views

3 months ago

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical Implicat…

Insights from 2023 ASCO® Annual Meeting

J. West

2.3K views

1 year ago

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

909 views

8 months ago

2024 Updates on the Fast-Changing NSCLC Landscape

Total Health

R. Osarogiagbon

447 views

8 months ago

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

499 views

5 months ago

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

263 views

1 month ago

Year in Review: Precision Medicine

Vivek Subbiah

948 views

10 months ago

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Luis Raez

465 views

5 months ago

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

E. Rodriguez

2.1K views

1 year ago

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

413 views

4 months ago

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

John Conibear

1.9K views

1 year ago

World Lung Cancer Day: Key Insights and Advances in Lung Cancer Trea…

Oncology Data Advisor

S. Kareff, B. Sandy, M. Vojnic

142 views

2 months ago

UChicago Medicine Best of ASCO® 2024: NSCLC

UChicago Medicine Annual Practice Updates in Hematology and Oncology

R. Thawani

218 views

2 months ago

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Clinical Imp…

Insights from 2023 ASCO® Annual Meeting

J. West

963 views

1 year ago

AUTOPLAY

Login

Login

Join VuMedi

2020 ESMO Updates in Lung Cancer: Does 1L Nivolumab–Ipilimumab Boost Unresectable Mesothelioma OS? Did the PACIFIC Trial Demonstrate Durable Benefit With Durvalumab After cCRT in Stage 3 NSCLC?

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Recommended

The Use of IO Doublet in PD-L1-Negative NSCLC

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Year in Review: Lung Cancer

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Hyperprogression in Cancer Treated With Immunotherapy

Mediastinal Staging of Lung Cancer

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical Implicat…

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

2024 Updates on the Fast-Changing NSCLC Landscape

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

Year in Review: Precision Medicine

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

World Lung Cancer Day: Key Insights and Advances in Lung Cancer Trea…

UChicago Medicine Best of ASCO® 2024: NSCLC

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Clinical Imp…